Literature DB >> 6335009

Impaired IL2 production by lymphocytes of patients with systemic lupus erythematosus.

P de Faucal, A Godard, M A Peyrat, J F Moreau, J P Soulillou.   

Abstract

The aim of this study was to define as possible abnormality of interleukin 2 (IL2) production by PHA-stimulated peripheral blood lymphocytes (PBL) in systemic lupus erythematosus (SLE). Thirty-four SLE PBL samples were stimulated to produce IL2 and compared with PBL from healthy (age- and sex-matched) controls. A significant defect in IL2 production was observed in SLE patients. This defect was not restricted to corticosteroid-treated patients and was not correlated with the presence of lymphotoxic antibodies or with clinical disease activity. Although 5-day responsiveness to phytohaemagglutinin (PHA) decreased in SLE, the SLE PHA-blasts responded as well as control blasts to semipurified IL2, suggesting that the receptor for IL2 was normally expressed on SLE blasts. In 9 cases, the effect of addition of indomethacin (2 micrograms/ml) or of an optimal amount of IL1 on PHA-induced IL2 production was studied. Indomethacin increased (22%) the IL2 yield of healthy individual PBL. In SLE, indomethacin (but not IL1) was able to completely restore (41% increase) the IL2 production of lectin-stimulated PBL (P less than 0.01). These data suggest that, in SLE, the inhibition of IL2 production is mediated by prostaglandin, possibly produced by monocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6335009     DOI: 10.1016/s0769-2625(84)81108-3

Source DB:  PubMed          Journal:  Ann Immunol (Paris)        ISSN: 0300-4910


  13 in total

1.  Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).

Authors:  J F Viallard; J L Pellegrin; V Ranchin; T Schaeverbeke; J Dehais; M Longy-Boursier; J M Ragnaud; B Leng; J F Moreau
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Interleukin-2 treatment reverses effects of cAMP-responsive element modulator α-over-expressing T cells in autoimmune-prone mice.

Authors:  K Ohl; A Wiener; A Schippers; N Wagner; K Tenbrock
Journal:  Clin Exp Immunol       Date:  2015-05-14       Impact factor: 4.330

3.  The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases.

Authors:  Lee Ann Garrett-Sinha; Alyssa Kearly; Anne B Satterthwaite
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 4.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Impaired T-cell activation in patients with systemic lupus erythematosus.

Authors:  S Sierakowski; E J Kucharz; R W Lightfoot; J S Goodwin
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

6.  The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity.

Authors:  Linda A Lieberman; George C Tsokos
Journal:  J Biomed Biotechnol       Date:  2010-06-06

Review 7.  [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance].

Authors:  K Ohl; K Tenbrock
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

8.  Functional T cell subpopulations responsible for hyposecretion of IL-2 in patients with systemic lupus erythematosus.

Authors:  T Hayama; N Kubo; E Ikeda; H Hashimoto; S Sawada; T Horie
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

9.  Interleukin-1-production by monocytes from patients with systemic lupus erythematosus.

Authors:  S Sierakowski; E J Kucharz; R W Lightfoot; J S Goodwin
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

10.  Production of human and murine interleukin-2 by toxic shock syndrome toxin-1.

Authors:  V V Micusan; G Mercier; A R Bhatti; R F Reiser; M S Bergdoll; D Oth
Journal:  Immunology       Date:  1986-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.